Core Viewpoint - The release of the first commercial health insurance innovative drug directory in China, which includes 19 innovative drugs, marks a significant step in building a multi-tiered medical security system, set to be implemented on January 1, 2026 [1] Group 1: Purpose of the Innovative Drug Directory - The establishment of the commercial health insurance innovative drug directory aims to alleviate the financial burden on patients by allowing high-value innovative drugs, which are not included in basic medical insurance, to be compensated through commercial health insurance [2] - This directory provides a clear policy interface and guidance on the range of drugs for commercial health insurance to participate in innovative drug coverage [2] Group 2: Focus Areas of the First Batch of Drugs - The first batch of 19 drugs comes from 18 companies, primarily focusing on new mechanisms and targets, including 9 first-class new drugs, which complement the basic medical insurance directory [3] - The drugs cover treatments for rare diseases such as CAR-T cell therapy, Gaucher disease, short bowel syndrome, and neuroblastoma, filling gaps in the current basic medical insurance coverage [3] Group 3: Understanding the "Three Exclusions" Principle - The "Three Exclusions" principle allows related drugs to be exempt from basic medical insurance self-payment rate assessments, excluded from monitoring for alternative products in centralized procurement, and their usage cases are not included in disease-based payment statistics [4] - This policy alleviates concerns for medical institutions regarding the use of innovative drugs, enabling patients to obtain these drugs directly in hospitals and settle through commercial insurance, thus enhancing drug accessibility [4] Group 4: Direct Benefits to Consumers - The release of the commercial health insurance innovative drug directory is expected to promote existing products like inclusive commercial health insurance, million medical insurance, and special drug insurance, making it easier for patients to access high-value drugs and receive compensation through commercial insurance [5] - Insurance companies benefit from a negotiated discount mechanism on the prices of drugs in the directory, which helps reduce their claims costs, and the directory provides a vetted list of drugs, lowering the selection and risk management costs in product design [5] - Cities like Beijing, Shanghai, and Guangzhou are exploring one-stop settlement services combining medical insurance and commercial insurance, which is expected to further enhance claims efficiency and user experience [5]

Core Insights - The release of the new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory marks a significant shift in China's healthcare system towards a dual-driven model of "basic medical insurance + commercial health insurance" [1][2] Group 1: Policy Changes - The new directories will be implemented on January 1, 2026, and represent a milestone in establishing a multi-tiered medical insurance system in China [2] - The Commercial Health Insurance Innovative Drug Directory provides a high-quality "drug pool" for insurance companies, reducing the barriers for product development and information asymmetry [2][3] - The basic medical insurance directory has added 114 new drugs, achieving a negotiation success rate of 88.19%, the highest in seven years, enhancing drug coverage in critical areas [3][4] Group 2: Drug Inclusion and Coverage - The first Commercial Health Insurance Innovative Drug Directory includes 19 drugs, focusing on high-value innovative treatments that exceed basic insurance coverage, such as CAR-T therapies and Alzheimer's drugs [4][5] - Five CAR-T therapies have been included in the directory, representing over half of the currently available products in China, with prices exceeding 1 million yuan for most [5][6] - The directory also includes treatments for rare diseases, demonstrating a commitment to vulnerable populations [6] Group 3: Market Dynamics - The dual-directory system is designed to address the structural challenges of high-value innovative drugs, allowing commercial insurance to cover these costs before they are potentially included in basic insurance [7][8] - The introduction of commercial insurance funding is expected to enhance the clinical drug level and overall R&D return rates for leading innovative pharmaceutical companies [6][11] Group 4: Consumer Impact - The new payment structure allows patients to access innovative therapies without facing the dilemma of full out-of-pocket costs, as commercial insurance will provide support [8][9] - The expansion of special drug lists in commercial insurance products is becoming a trend, with many regions updating their offerings to include high-value cancer and rare disease medications [9][10] - However, challenges remain in ensuring that hospitals stock these high-cost drugs and that the claims process is efficient and transparent [10]

Core Viewpoint - The National Medical Security Work Conference held in December 2025 emphasizes the optimization of centralized procurement policies, the development of maternity and long-term care insurance, and the strategic purchasing role of medical insurance to support the innovative drug industry [1][2]. Group 1: Support for Commercial Health Insurance - The National Medical Security Bureau will support the integration and complementary development of commercial health insurance with basic medical insurance, encouraging the inclusion of more reasonable medical expenses outside the basic medical insurance catalog into the coverage of commercial health insurance [2]. - There will be an encouragement for commercial health insurance institutions to expand their investment in innovative drugs, promoting research and development in this area [2]. - A one-stop settlement service combining "medical insurance + commercial insurance" will be provided for eligible commercial health insurance products, aimed at improving claims efficiency [2]. Group 2: Development of Maternity and Long-term Care Insurance - The National Medical Security Bureau aims to include flexible employment personnel, migrant workers, and new employment forms in the coverage of maternity insurance [2]. - The goal is to achieve "no out-of-pocket" expenses for childbirth within the policy scope nationwide, with enhancements to prenatal examination medical expense coverage [2]. - The long-term care insurance system will be comprehensively promoted, with encouragement for commercial insurance institutions to develop commercial long-term care insurance products [2]. Group 3: Support for Pharmaceutical Industry Innovation - The National Medical Security Bureau will guide the pharmaceutical industry towards healthy competition and differentiated innovation, implementing measures to support the high-quality development of innovative drugs [3]. - New rounds of national centralized procurement for drugs and high-value medical consumables will be conducted, with a focus on improving the efficiency of enterprise returns [3]. - The multi-price discovery function of the Chinese drug price registration system will be leveraged to assist the Chinese pharmaceutical industry in expanding internationally [3].

按病种付费清算是清算的重点和难点。《三年行动计划》提出，省级医保部门要指导统筹地区，将 按病种付费相关工作分解到平时，注重日常的沟通协商和争议处理，及时解决问题，减少矛盾积压。用 好特例单议、意见收集反馈、谈判协商、数据工作组等工作机制，不断完善审核反馈渠道，重视和提升 医疗机构、医务人员在清算中的参与度，促进医保和医疗数据共享共通，提高医药机构对清算工作认 可，促进清算时效不断提高。同时，要严格履行定点服务协议，及时足额向定点医药机构拨付协议约定 的医保资金，不得拖欠医药费用。 《三年行动计划》鼓励充分发挥试点的典型示范、辐射带动作用，清算进度要快于全国平均进度。 各省做好组织推荐，原则上试点统筹地区2个左右，至少1个开展季度清算，支持有条件的省份，全省试 点。鼓励直辖市要全面推进试点，提前完成清算任务。国家医保局将加强对试点的指导和支持，及时总 结经验，形成和推广可复制做法，推进目标任务的全面实现。 人民网北京12月15日电 （记者乔业琼）据国家医保局官网消息，为健全医疗、医保、医药协同发 展和治理机制，进一步优化医保基金结算管理，加快构建与"1+3+N"多层次医疗保障体系相适应的科学 结算体系，全面提高 ...

Core Viewpoint - The release of the 2025 National Medical Insurance Drug List and the first version of the Commercial Insurance Innovative Drug List marks a significant step in the construction of a multi-tiered medical security system, balancing basic healthcare coverage with diverse options [1] Group 1: Dual Directory System - The introduction of the "dual directory" system signifies a collaborative approach between basic medical insurance and commercial insurance, ensuring that essential medications are covered while also allowing for the inclusion of high-value innovative drugs [1] - This system adheres to the principle of "basic insurance for basic needs," preventing high-priced drugs from overwhelming the insurance fund [1] Group 2: Future Directions - Future efforts are needed to break down data barriers between basic medical insurance and commercial insurance, aiming to establish a one-stop settlement system for "medical insurance + commercial insurance" [1] - Continuous exploration and optimization by relevant departments are essential to enhance the roles of medical insurance as a safety net and commercial insurance as an expansion tool, ultimately improving health security for over 1.4 billion people [1]

Core Insights - The article discusses the rapid expansion and challenges of "Hui Min Bao," a low-cost health insurance product in China that aims to alleviate high medical expenses for families, particularly in the context of rising healthcare costs since its inception in Shenzhen in 2015 [1][4]. Group 1: Product Overview - "Hui Min Bao" offers low premiums, typically ranging from 50 to 300 yuan annually, with coverage amounts generally exceeding 400,000 yuan, targeting high out-of-pocket medical expenses and specific high-cost medications [2][3]. - The product has evolved to include various types of coverage, such as supplementary compensation for out-of-pocket expenses after basic insurance, coverage for non-insured medical expenses, and specific protections for high-cost drugs and services [3]. Group 2: Challenges and Risks - The program faces dual pressures of participation and renewal rates, compounded by adverse selection and moral hazard due to its low entry barriers, which attract higher-risk individuals [4][6]. - There are concerns regarding the unclear boundaries of responsibility and governance structures, particularly the role of government versus commercial operations in the program [4][5]. Group 3: Recommendations for Improvement - Experts suggest that a unified operational standard and risk-sharing mechanism should be established to enhance the stability of the insurance model [5][6]. - Product differentiation and targeted designs for specific demographics, such as the elderly and chronic patients, are recommended to address the issue of product homogeneity [6][7]. Group 4: Ecosystem Development - A collaborative framework involving policymakers, regulatory bodies, insurance companies, and third-party service providers is essential for creating a resilient "Hui Min Bao+" ecosystem [7][8]. - The article emphasizes the need for balancing affordability and commercial sustainability while leveraging technology for improved service delivery and claims processing [6][8].

热潮之下，一系列关乎其"生命力"的根本性问题也逐渐浮出水面：在政府"指导"与保险公司"承办"的混合模式下，如何确保项目的长期稳健运行？当最初的 投保热情褪去，如何应对可能出现的参保率"瓶颈"与"死亡螺旋"风险？这块旨在补齐多层次医疗保障体系短板的"关键拼图"，能否从一时的"爆红"走向持续 的"长红"，真正打磨成一件经得起时间与风险考验的公共产品？ 全国开花 惠民保最早的雏形可追溯至2015年深圳率先推出的重特大疾病补充医疗险。2020年开始，兼具普惠性与地域特色的"城市定制型商业医疗保险"如雨后春笋般 在全国各地涌现。短短几年时间，这项普惠保险惠及上亿人次。 "一年最低几十元，可享受百万元保障。"这一宣传语早已传遍大街小巷。自2020年以来，惠民保已从深圳蔓延至全国上百个城市，并迅速成为普惠金融与健 康中国交汇点上的现象级产品。惠民保可以对动辄数十万元的特药费用、高额自付医疗费用进行补充报销，承载了无数家庭对"看病贵"难题纾解的期望。 在业内人士看来，为了最大限度地实现普惠，惠民保普遍放宽甚至取消了健康告知，吸引了更多已患病或健康风险较高的人群集中投保。如果产品定价时未 能充分预见这一风险，或者风险准备金计提 ...

Core Viewpoint - The introduction of the "dual directory" system for innovative drugs in China is expected to create significant opportunities for the sector, with a clearer boundary between "basic insurance" and "promoting innovation" [10][12][16]. Group 1: Impact of the "Dual Directory" System - The "dual directory" system establishes a dual-driven payment system of "basic medical insurance + commercial insurance," enhancing the payment environment for innovative drugs [10][12]. - The 2025 updated medical insurance directory includes a record 50 first-class innovative drugs, with a negotiation success rate of 88%, indicating a shift towards valuing clinical efficacy over price [12][14]. - The first commercial insurance directory includes 19 high-value drugs, providing a payment outlet for previously unaffordable treatments, thus addressing patient payment challenges and offering pharmaceutical companies a secondary payment tier [12][14]. Group 2: Current Market Stage and Future Outlook - The innovative drug sector is currently in a phase of industry-wide valuation recovery, with a shift in focus towards the realization of corporate performance [20][21]. - The market is expected to transition from broad valuation reassessment to a focus on fundamental performance, with 2025 marking a year of renewed recognition for the innovative drug industry [20][21]. - The sector is anticipated to experience significant growth driven by the successful commercialization of innovative drugs and the accumulation of real-world data [17][20]. Group 3: Investment Opportunities and Strategies - Current market conditions present a golden window for medium to long-term capital allocation, with many innovative drug companies at historically low valuation levels [23][25]. - Investment strategies should focus on selecting high-quality companies with strong R&D capabilities and commercial potential, particularly those with global competitiveness [29][30]. - The emphasis should be on identifying companies that can effectively translate scientific innovation into commercial success, as future returns will depend on precise stock selection [29][30]. Group 4: Other Notable Sectors - Beyond innovative drugs, attention should also be given to high-end medical devices and the pharmaceutical R&D outsourcing industry, which are expected to benefit from macroeconomic trends and increased demand [31][32].

Core Viewpoint - The article discusses the opportunities and challenges in the innovative drug sector following the implementation of the "dual directory" system, which establishes a dual payment mechanism of basic medical insurance and commercial insurance, enhancing the clarity between "basic protection" and "promoting innovation" [3][15]. Group 1: Impact of the "Dual Directory" System - The "dual directory" system is expected to accelerate the commercialization of innovative drugs by providing a mechanism for high-value drugs to enter the commercial insurance directory without significant price reductions [21][22]. - The new medical insurance directory includes a record number of 50 class 1 innovative drugs with a negotiation success rate of 88%, indicating a shift towards valuing clinical efficacy over price [17][19]. - The introduction of the commercial insurance directory marks a milestone by including 19 high-value drugs, addressing patient payment challenges and providing a secondary payment tier for pharmaceutical companies [17][19]. Group 2: Current Market Stage and Valuation - The innovative drug sector is currently in a phase of valuation recovery, with a focus shifting from broad valuation reassessment to concrete fundamental performance [15][26]. - The market is expected to see significant growth in 2026, driven by the successful commercialization of innovative drugs and the release of important clinical data [29][30]. - The current valuation of innovative drug companies is considered attractive, especially after recent adjustments, with many companies positioned for potential growth in the coming years [30][31]. Group 3: Investment Strategies and Focus Areas - Investment strategies should focus on companies with sustainable growth potential, particularly those demonstrating strong research and development capabilities and commercial viability [35][36]. - Key areas of interest include advanced medical devices, innovative drug development, and sectors related to the pharmaceutical supply chain, which are expected to benefit from macroeconomic trends [37][38]. - The emphasis should be on selecting individual stocks with strong fundamentals rather than investing broadly in the sector, as the market becomes more discerning [35][36].

Investment Rating - The report maintains an "Optimistic" rating for the industry and a "Buy" rating for Heng Rui Medicine (600276) [52] Core Insights - The newly released basic medical insurance drug directory and the first commercial health insurance innovative drug directory support the development of innovative drugs and promote the complementary relationship between commercial health insurance and basic medical insurance [9][12] - A total of 114 new drugs have been added to the directory, including 50 first-class innovative drugs, while 29 drugs have been removed due to lack of clinical supply or better alternatives [11][12] - The report emphasizes the importance of monitoring the volume growth of pharmaceutical companies' products after entering the insurance directory and the investment opportunities arising from the optimization of payment structures for innovative drug companies [51] Industry News - The new basic medical insurance drug directory and the first commercial health insurance innovative drug directory were published, with the new directory set to take effect on January 1, 2026 [9] - The first commercial health insurance innovative drug directory includes 19 drugs, which complement the basic medical insurance and support the establishment of a multi-tiered medical security system [12] - The first CDK2/4/6 inhibitor developed by China Biopharmaceutical has been approved for market launch, indicating advancements in innovative drug development [14] Company Announcements - Heng Rui Medicine has successfully included several drugs in the national medical insurance directory through negotiations, enhancing its market position [31] - Stone Pharmaceutical Group has received acceptance for its second marketing authorization application for Semaglutide injection [29] - Junshi Biosciences has had its new drug application for the injection of Nocadizumab accepted [32] Market Review - For the week of December 5 to December 11, 2025, the SW Pharmaceutical and Biological Index fell by 0.78%, with most sub-sectors experiencing declines [40] - As of December 11, 2025, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) was 50.70, with a valuation premium of 265% relative to the CSI 300 [44] Weekly Strategy - The report suggests focusing on the growth potential of pharmaceutical companies' products after entering the insurance directory and the investment opportunities in the CXO and upstream life sciences sectors [51]